Mirikizumab Clinical Trials
7 recruitingDrug
Phase 34Phase 22Phase 41
Showing 1–7 of 7 trials
Recruiting
Phase 3
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Inflammatory Bowel DiseasesCrohn's DiseaseUlcerative Colitis+1 more
Eli Lilly and Company150 enrolled65 locationsNCT04844606
Recruiting
Phase 3
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Crohn's Disease
Eli Lilly and Company90 enrolled81 locationsNCT05509777
Recruiting
Phase 2
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Ulcerative Colitis
Eli Lilly and Company252 enrolled147 locationsNCT07186101
Recruiting
Phase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ulcerative ColitisObesity or Overweight
Eli Lilly and Company350 enrolled193 locationsNCT06937086
Recruiting
Phase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Crohn's DiseaseObesity or Overweight
Eli Lilly and Company290 enrolled188 locationsNCT06937099
Recruiting
Phase 2
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Ulcerative ColitisUlcerative Colitis Chronic
Eli Lilly and Company140 enrolled207 locationsNCT06598943
Recruiting
Phase 4
Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis
Ulcerative Colitis (UC)
University Hospital Schleswig-Holstein300 enrolled1 locationNCT07235904